U.S. Markets closed

Chembio Diagnostics, Inc. (CEMI)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.6746-0.0284 (-4.04%)
At close: 04:00PM EDT
0.6800 +0.01 (+0.80%)
After hours: 07:48PM EDT

Chembio Diagnostics, Inc.

555 Wireless Boulevard
Hauppauge, NY 11788
United States
631 924 1135

IndustryDiagnostics & Research
Full Time Employees337

Key Executives

NameTitlePayExercisedYear Born
Mr. Richard L. EberlyPres, CEO & Director664.13kN/A1961
Mr. Javan EsfandiariExec. VP and Chief Scientific & Technology Officer508.22kN/A1967
Mr. Lawrence J. Steenvoorden CPAExec. VP, CFO & Sec.N/AN/A1971
Mr. Paul J. AngelicoEVP & COON/AN/A1957
Dr. Robert Passas Ph.D.VP of International Sales & Bus. Devel.N/AN/A1954
Ms. Stella RiveraVP of HRN/AN/AN/A
Mr. Charles CasoSr. VP of Global Commercial OperationsN/AN/A1962
Dr. Konstantin LyashchenkoResearch Director of Chembio Diagnostic Systems IncN/AN/AN/A
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Chembio Diagnostics, Inc., together with its subsidiaries, develops, manufactures, and commercializes point-of-care (POC) diagnostic tests that are used to detect or diagnose diseases. The company offers tests for COVID-19, HIV and Syphilis, and Zika virus. It also develops tests for malaria, dengue, chikungunya, Chagas, ebola, leishmaniasis, lassa, marburg, leptospirosis, rickettsia, and Burkholderia diseases. The company sells its products under the STAT-PAK, SURE CHECK, STAT VIEW, and DPP trademarks, as well as sells its products directly through distributors to medical laboratories and hospitals, governmental and public health entities, non-governmental organizations, medical professionals, and retail establishments in the United States and internationally. It has collaboration agreements with Bill & Melinda Gates Foundation, The Paul G. Allen Family Foundation, The Oswaldo Cruz Foundation, and the Foundation for Innovative New Diagnostics, as well as U.S. government agencies, such as Centers for Disease Control and Prevention, the Biomedical Advanced Research and Development Authority of the U.S. Department of Health and Human Services, and the U.S. Department of Agriculture. Chembio Diagnostics, Inc. was founded in 1985 and is headquartered in Hauppauge, New York.

Corporate Governance

Chembio Diagnostics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.